Silexion Therapeutics Corp
SLXN· Nasdaq
SLXNSilexion Therapeutics Corp
Filed May 13, 2025 · 10-Q · 43 days after period end · 0001178913-25-001761
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Income | -$1.74M | -$1.42M |
| EPS Diluted | $3.84 | $12.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Silexion Therapeutics Corp · CIK 2022416 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end
